Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Melt Pharmaceuticals announced favorable top-line results from its phase 1 PK study of MELT-210, a 3 mg sublingual midazolam tablet. The study involving 23 patients compared MELT-210 with IV midazolam and achieved concentration goals. CEO Larry Dillaha expressed optimism about the results, viewing it as a milestone for an IV-free sedation option. The next step includes discussions with the FDA regarding further clinical development. MELT-210 utilizes Catalent's proprietary Zydis® technology, with no FDA-approved equivalent products.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW) announced participation in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference. CEO Mark L. Baum and CFO Andrew Boll will present virtually on April 27, 2022, at 2:00 p.m. ET. A live webcast will be accessible on Harrow's website, with a replay available post-event. Harrow Health focuses on ophthalmic healthcare, owning ImprimisRx and Visionology, and holds equity in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q1 2022 on May 5, 2022, post market close. The company, which focuses on ophthalmic healthcare, will also host a conference call at 4:45 PM ET to discuss the results and provide a business update. A webcast will be available for replay until August 5, 2022. Details of the event, including participation dial-ins and replay options, can be found on their website. This update is pertinent for investors and stakeholders tracking financial performance and corporate developments.
Harrow Health, Inc. (HROW) has appointed Perry J. Sternberg and Dr. Marty Makary to its Board of Directors, effective immediately, while Robert J. Kammer has resigned. Sternberg brings extensive commercial experience from leading eye care companies, and his expertise in strategic marketing is expected to aid in launching new FDA-approved products like AMP-100. Dr. Makary, with a strong background in healthcare policy and innovation, aligns with the company's mission of making medicines accessible. This restructuring aims to strengthen governance and support Harrow's goal of becoming a leading U.S. eye care company.
Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $20.2 million for Q4 2021, marking a 38% increase year-over-year. Gross profit also reached $15.1 million, a 42% rise, with a gross margin of 75%. The FDA accepted the NDA for AMP-100 with a PDUFA target date of October 16, 2022. Commissions from DEXYCU® sales hit $1.0 million, driven by record unit volumes. The company ended 2021 with $42.2 million in cash and equivalents, providing a strong foundation for future growth.
Melt Pharmaceuticals announces the appointment of Brad Osborne as Chief Financial Officer, bringing over 20 years of finance experience, including a decade at Precigen. His expertise spans IPOs, M&A, and SEC compliance. Dr. Larry Dillaha, CEO, emphasizes Osborne's significant role in guiding the company through its ongoing Phase 2 efficacy study for MELT-300 and advancing their patented MELT technology. Melt focuses on non-intravenous and non-opioid sedation solutions, carved out from Harrow Health in 2019, catering to over 100 million medical procedures in the U.S.
Harrow Health (NASDAQ: HROW), an ophthalmic healthcare company, will report its financial results for Q4 and the full year 2021 on March 10, 2022, after market close. A conference call is scheduled for 4:45 p.m. ET the same day to discuss results and provide business updates. Investors can access the Letter to Stockholders on the company's website following the earnings release. Harrow Health focuses on ophthalmic pharmaceuticals through its subsidiaries, ImprimisRx and Visionology.
Harrow Health, Inc. (Nasdaq: HROW) announced that the FDA has accepted its New Drug Application (NDA) for AMP-100, aimed at ocular surface anesthesia. The application has a PDUFA date of October 16, 2022.
CEO Mark L. Baum emphasized that if approved, AMP-100 would be the first non-opioid ophthalmic drug of its kind in the U.S. Harrow Health is committed to making this innovative drug commercially available to ophthalmologists and surgery centers nationwide.
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (NASDAQ: HROW) has released its inaugural 2022 Corporate Transparency Report, emphasizing its commitment to making sight-saving medications accessible. CEO Mark L. Baum highlights sustainable business practices aimed at benefiting customers and communities. The report details the company’s dedication to innovation, quality, and ethical standards while maintaining strong corporate governance. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in affiliated companies. The report is available in the Investors section of the company’s website.